Patient-derived xenografts: a promising resource for preclinical cancer research

Patient-derived xenograft tumors retain molecular and histopathological features of the originating tumor and are useful preclinical tools for drug discovery and assessment. We recently reported that ‘rapid’ engraftment of head and neck squamous cell carcinoma samples is highly prognostic and correl...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamboulas, Christina, Ailles, Laurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370391/
https://www.ncbi.nlm.nih.gov/pubmed/30788424
http://dx.doi.org/10.1080/23723556.2018.1558684
_version_ 1783394358672752640
author Karamboulas, Christina
Ailles, Laurie
author_facet Karamboulas, Christina
Ailles, Laurie
author_sort Karamboulas, Christina
collection PubMed
description Patient-derived xenograft tumors retain molecular and histopathological features of the originating tumor and are useful preclinical tools for drug discovery and assessment. We recently reported that ‘rapid’ engraftment of head and neck squamous cell carcinoma samples is highly prognostic and correlates with deregulation of the G1/S checkpoint. Tumors with genetic alterations in cyclinD1 (CCND1) and/or cyclin-dependent kinase inhibitor 2A (CDKN2A) are more likely to respond to abemaciclib.
format Online
Article
Text
id pubmed-6370391
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-63703912020-01-08 Patient-derived xenografts: a promising resource for preclinical cancer research Karamboulas, Christina Ailles, Laurie Mol Cell Oncol Author’s Views Patient-derived xenograft tumors retain molecular and histopathological features of the originating tumor and are useful preclinical tools for drug discovery and assessment. We recently reported that ‘rapid’ engraftment of head and neck squamous cell carcinoma samples is highly prognostic and correlates with deregulation of the G1/S checkpoint. Tumors with genetic alterations in cyclinD1 (CCND1) and/or cyclin-dependent kinase inhibitor 2A (CDKN2A) are more likely to respond to abemaciclib. Taylor & Francis 2019-01-08 /pmc/articles/PMC6370391/ /pubmed/30788424 http://dx.doi.org/10.1080/23723556.2018.1558684 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Karamboulas, Christina
Ailles, Laurie
Patient-derived xenografts: a promising resource for preclinical cancer research
title Patient-derived xenografts: a promising resource for preclinical cancer research
title_full Patient-derived xenografts: a promising resource for preclinical cancer research
title_fullStr Patient-derived xenografts: a promising resource for preclinical cancer research
title_full_unstemmed Patient-derived xenografts: a promising resource for preclinical cancer research
title_short Patient-derived xenografts: a promising resource for preclinical cancer research
title_sort patient-derived xenografts: a promising resource for preclinical cancer research
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370391/
https://www.ncbi.nlm.nih.gov/pubmed/30788424
http://dx.doi.org/10.1080/23723556.2018.1558684
work_keys_str_mv AT karamboulaschristina patientderivedxenograftsapromisingresourceforpreclinicalcancerresearch
AT ailleslaurie patientderivedxenograftsapromisingresourceforpreclinicalcancerresearch

Ejemplares similares